Ligand Pharmaceuticals General Stock Net Income
| LGNYZ Stock | USD 0.01 0.00 0.00% |
Ligand Pharmaceuticals General fundamentals help investors to digest information that contributes to Ligand Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Ligand Pink Sheet. The fundamental analysis module provides a way to measure Ligand Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ligand Pharmaceuticals pink sheet.
Ligand |
Ligand Pharmaceuticals General Company Net Income Analysis
Ligand Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Ligand Pharmaceuticals Net Income | 57.14 M |
Most of Ligand Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ligand Pharmaceuticals General is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Ligand Pharmaceuticals General reported net income of 57.14 M. This is much higher than that of the Other sector and significantly higher than that of the Other industry. The net income for all United States stocks is notably lower than that of the firm.
Ligand Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ligand Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Ligand Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ligand Pharmaceuticals by comparing valuation metrics of similar companies.Ligand Pharmaceuticals is currently under evaluation in net income category among related companies.
Ligand Fundamentals
| Revenue | 277.13 M | |||
| EBITDA | 98.42 M | |||
| Net Income | 57.14 M | |||
| Cash Flow From Operations | 78.8 M | |||
| Total Asset | 1.3 B | |||
| Net Asset | 1.3 B |
About Ligand Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ligand Pharmaceuticals General's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ligand Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ligand Pharmaceuticals General based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Ligand Pink Sheet analysis
When running Ligand Pharmaceuticals' price analysis, check to measure Ligand Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ligand Pharmaceuticals is operating at the current time. Most of Ligand Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ligand Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ligand Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ligand Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |